The aim of this study was to produce hydrogels for topical use and having strengthened anti-inflammatory, analgesic and antirheumatic activity. To obtain the above effect dry standardized plant extract was added to enrich a formulation containing therapeutic agent (ketoprofen) from the group of nonsteroidal anti-inflammatory drugs. Dry standardized extract from Solidago virgaurea L. of confirmed anti-inflammatory activity was selected for this purpose. The derivatives of acrylic acid polymers (Carbopol Ultrez and Carbopol 980) were used as the formulation vehicles. These vehicles were selected owing to their high applicative properties--transparency, resistance to changes of temperature, perfect tactile and esthetic qualities, no sensitizing agents, no toxicity and lack of influence on therapeutic properties of the therapeutic agent and compatibility in the pharmaceutical phase. The produced formulations were exposed to basic physicochemical tests--pH, viscosity parameters (structural viscosity, yield stress and thixotropy), pharmaceutical availability and durability after six months of storage. The effect of component plant extracts on the process of ketoprofen diffusion to acceptor fluid through a semipermeable membrane was also compared. The obtained results indicate that dry standardized extract from Solidago virgaurea L. does not affect significantly the process of ketoprofen release from the tested preparations. After six months of storage the preparations with ketoprofen demonstrate rheological stability and high pharmaceutical availability.
Download full-text PDF |
Source |
---|
JAMA Psychiatry
January 2025
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Importance: Depressive symptoms are associated with cognitive decline in older individuals. Uncertainty about underlying mechanisms hampers diagnostic and therapeutic efforts. This large-scale study aimed to elucidate the association between depressive symptoms and amyloid pathology.
View Article and Find Full Text PDFAdv Ther
January 2025
School of Population Health, University of New South Wales, Sydney, Australia.
Hypertension, dyslipidemia, and type 2 diabetes are highly prevalent and poorly controlled cardiometabolic diseases in the Middle East. Therapeutic non-adherence and therapeutic inertia are major contributors to this suboptimal disease control. Regardless of the cardiometabolic disease, evidence-based solutions may be used to improve therapeutic non-adherence and overcome inertia, and thereby help to alleviate the heavy burden of cardiovascular disease in the Middle East.
View Article and Find Full Text PDFMol Divers
January 2025
Department of Biosciences, Faculty of Science, Universiti Teknologi Malaysia, 81310, Johor Bahru, Johor, Malaysia.
Dengue is one of the most prevalent viruses transmitted by the Aedes aegypti mosquitoes. Currently, no specific medication is available to treat dengue diseases. The NS2B-NS3 protease is vital during post-translational processing, which is a key target in this study.
View Article and Find Full Text PDFBioconjug Chem
January 2025
Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.
Lipidated analogues of glucagon-like peptide 1 (GLP-1) have gained enormous attention as long-acting peptide therapeutics for type 2 diabetes and also antiobesity treatment. Commercially available therapeutic lipidated GLP-1 analogues, semaglutide and liraglutide, have the great advantage of prolonged half-lives of hours and days instead of minutes as is the case for native GLP-1. A crucial factor in the development of novel lipidated therapeutic peptides is their physical stability, which greatly influences manufacturing and drug product development.
View Article and Find Full Text PDFTijdschr Psychiatr
January 2025
Background: Brexanolone (Zulresso) and zuranolone (Zurzuvae) are two synthetic neuroactive steroids that were approved by the U.S. Food and Drug Administration in March 2019 (as an intravenous treatment) and August 2023 (as an oral treatment) respectively, for the treatment of postpartum depression.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!